RPL17 and neoplasm: Programmed Death Receptor 1/Programmed Death Receptor Ligand 1 (PD 1/PD-L1) and Cytotoxic T Lymphocytes Antigen 4 (CTLA-4) inhibitors are agents able to target specific pathways related to immune-response which are often hyper-activated by tumor cell interaction (46).